COMMUNIQUÉS West-GlobeNewswire
-
Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided
26/06/2026 -
LIXTE Joins Russell Microcap Index
26/06/2026 -
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
26/06/2026 -
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
26/06/2026 -
Standard Dental Labs Inc. Signs Letter of Intent to Acquire Additional Dental Laboratory in the Tampa Bay Region
26/06/2026 -
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
26/06/2026 -
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
26/06/2026 -
Thought Leadership & Innovation Foundation Founder Bill Oldham Launches New Book: Beyond Better Data: What Actually Changes Health Care?
26/06/2026 -
Sienna Completes Acquisition in Greater Ottawa Area
26/06/2026 -
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
26/06/2026 -
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development
26/06/2026 -
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
26/06/2026 -
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
26/06/2026 -
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
26/06/2026 -
Fortrea Names Jason Knoblauch as Chief Financial Officer
26/06/2026 -
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
26/06/2026 -
CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma
26/06/2026 -
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
26/06/2026 -
Complex Small Molecules Are Changing Drug R&D
26/06/2026
Pages